CClinicalTrials.gg
RecruitingNCT04842162MAGNOLIAUpdated Nov 26, 2025

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

A Phase 2 interventional study of indocyanine green in Head and Neck Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 2, Interventional, and Diagnostic

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2020, registered Apr 2021).
  • Started Dec 2020; still recruiting 5 years 9 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers

02

Conditions studied

  • Head and Neck Cancer
03

In context

Head and Neck Neoplasms

2,344 studies on the registry are indexed under Head and Neck Neoplasms; 552 are open to participants now.

This study's planned enrollment of 65 is above the median of 47 across 1,751 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 242 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female 18 years of age or older
  • ECOG performance status 0-2
  • Histological confirmation of squamous cell carcinoma
  • Locating the primary tumour in the oral cavity or oropharynx
  • Disease operable for complete resection
  • Serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age
  • Patient information and signed free and informed consent
  • Patient affiliated with a social security scheme or beneficiary of a similar scheme.
  • The patient must understand, sign and date the consent form prior to any protocol-specific procedures. The patient must be able and willing to comply with the study visits and procedures described in the protocol

Exclusion criteria

Exclusion Criteria:

  • Severe medical co-morbidities or contraindications to surgery
  • Primary tumour not operable
  • History of head and neck cancer in the past 5 years
  • History of radiation for head and neck cancer
  • Metastatic cancer
  • Tumours with necrosis ranges in pre-operative imaging
  • History of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers.
  • Pregnant or nursing woman
  • Allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans.
  • Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin.
  • Documented coronary artery disease
  • Advanced renal failure (creatinine > 1.5mg/dL).
  • Within 2 weeks prior to inclusion, concomitant medication that reduces or increases extinction of GI (i.e. anticonvulsants, haloperidol and Heparin).
  • Patient under guardianship or curatorship or deprived of liberty by judicial or administrative decision or patient unable to give consent.
  • Patients unable to undergo medical follow-up of the trial
05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Patients with head and neck cancer

    Drug: indocyanine green

Interventions

  • Drugindocyanine green

    indocyanine green (INFRACYANINE© 25mg/10mL).

06

What researchers measure

Primary outcomes

  1. Sensitivity of Near Infrared Fluorescence Imaging

    Sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after complete macroscopic surgical resection. For the calculation of the sensitivity, for each operating room we consider the first section and the last section in which the pathological analysis confirms the presence of microscopic residual disease. Patients for whom near-infrared fluorescence imaging detects disease are classified as true positives (TP). Sensitivity is defined as the number of TP divided by the total number of patients N.

    Time frame: at surgery

07

Study locations

2 of 2 sites recruiting
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
    • Antoine DIGONNET · Contact
    Recruiting
  • Gustave Roussy
    Villejuif, Val De Marne 94800, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04842162
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Responsible party
Sponsor
First posted
Apr 13, 2021
Start date
Dec 15, 2020
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Nov 26, 2025

Study contacts

Philippe Gorphe, MD
Contact
philippe.gorphe@gustaveroussy.fr
+33 (0)1 42 11 42 11

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion